E
Emerald Therapeutics
Emerald Therapeutics is building technology platforms to drive the future of biotechnology innovation
About Emerald Therapeutics
Emerald Cloud Lab (ECL) is a pioneering company in the life sciences sector, offering a virtual laboratory platform that allows scientists to conduct and manage experiments remotely. Founded by scientists, ECL aims to eliminate the routine tasks that often bog down laboratory work, enabling researchers to focus on orchestrating science rather than performing manual labor. The company's core product is a cloud-based lab environment that provides access to a wide range of scientific instruments and automation tools, making it easier for scientists to execute complex experiments from anywhere in the world.
Read full description
ECL primarily serves researchers and organizations in the life sciences industry, including academic institutions, pharmaceutical companies, and biotech firms. The platform is designed to cater to scientists who require high levels of precision and efficiency in their experimental workflows. By virtualizing the laboratory, ECL helps its clients save time and resources, thereby accelerating the pace of scientific discovery and innovation.
The business model of Emerald Cloud Lab revolves around subscription-based access to its virtual lab platform. Clients pay for the use of the platform and its associated services, which include access to scientific instruments, data management, and analytical tools. This model ensures a steady stream of recurring revenue for the company, while also providing flexibility for clients to scale their usage based on their specific needs.
In summary, Emerald Cloud Lab is revolutionizing the way scientific research is conducted by offering a virtual laboratory platform that enhances efficiency and innovation. The company serves a diverse range of clients in the life sciences sector and operates on a subscription-based business model.
At a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Menlo Park, United States
- Employees
- 206
- Open positions
- None listed
- Dealroom signal
- 82.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Arts & Culture, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Emerald Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jun 2015 | $21M | $82M | Western Technology Investment · Founders Fund · Schooner Capital · OS Fund | — |
| SERIES B✓Equity / VC | Mar 2014 | $6M | $24M | Max Levchin · Founders Fund · Schooner Capital | — |
Growth signals
Latest recorded traffic for Emerald Therapeutics is 60 monthly website visits. Emerald Therapeutics's team grew 25.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
James Hong
Max Levchin
Founders Fund
Schooner Capital
Series B and later3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Emerald Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emerald Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.